(62 days)
Audit™ MicroFD™ BNP Control is an assayed bi-level reference control consisting of human plasma based solutions. It is intended to simulate human patient plasma samples for the purpose of monitoring the precision and to detect systematic analytical deviations of laboratory testing procedures for both BNP-32 and NT-proBNP assays.
Audit™ MicroFD™ BNP Control is an assayed bi-level reference control consisting of human plasma based solutions.
This document is a 510(k) premarket notification decision letter from the FDA for a quality control material, not a medical device that requires a study to prove its performance against acceptance criteria in the typical sense of diagnostic or therapeutic devices. Therefore, a table of acceptance criteria and device performance, and details about studies with ground truth, experts, sample sizes, and adjudication methods are not applicable here.
This document pertains to the Audit™ MicroControl MicroFDTM BNP Control, which is a quality control material. Its purpose is to monitor the precision and detect systematic analytical deviations of laboratory testing procedures for BNP-32 and NT-proBNP assays.
The FDA's decision is that the device is substantially equivalent to legally marketed predicate devices, meaning it does not require a premarket approval application (PMA). This determination is based on the device meeting the requirements for general controls provisions of the Act, which include annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
Therefore, the request for acceptance criteria and study details cannot be fulfilled from the provided document. The document does not describe performance metrics (like sensitivity, specificity, accuracy) for a diagnostic device, nor does it detail a clinical study with an aim to prove such performance. Instead, it confirms the regulatory clearance of a quality control product.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes entwined around it, representing medicine and healing. The caduceus is surrounded by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement. The logo is black and white and has a simple, clean design.
SEP - 9 2003
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Alan J. Vekich Senior Scientist Aalto Scientific Ltd. 1959 Kellogg Avenue Carlsbad, CA 92008
Re: K032122
Trade/Device Name: Audit™ MicroControl MicroFDTM BNP Control Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJY Dated: July 3, 2003 Received: August 6, 2003
Dear Mr. Vekich:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Page 1 of 1
| 510(k) Number (if known): | K032122 |
|---|---|
| Device Name: | Audit MicroControl MicroFD BNP Control |
Indications For Use:
Audit™ MicroFD™ BNP Control is an assayed bi-level reference control consisting of human plasma based solutions. It is intended to simulate human patient plasma samples for the purpose of monitoring the precision and to detect systematic analytical deviations of laboratory testing procedures for both BNP-32 and NT-proBNP assays.
(PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| Cawl C Benson for Jean Cooper. DVM | |
| Division Sign-Off |
Office of In Vitro Diagnostic Device
Evaluation and Safety
| 510(k) | K032122 |
|---|---|
| -------- | --------- |
| Prescription Use(Per 21 CFR 801.109) | OR | Over-The-Counter Use |
|---|---|---|
| ------------------------------------------ | ---- | ---------------------- |
(Optional Format 1-2-96)
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.